TL;DRUPS is investing $48 million in 27 temperature-controlled freight facilities across three continents as demand for biologics and GLP-1 drugs reshapes pharmaceutical logistics. The company is targeting $20 billion in healthcare revenue by end of 2026.
UPS has announced a $48 million investment in 27 temperature-controlled freight cross-dock facilities spanning the Americas, Europe, and Asia. The facilities are designed for short-term storage between air and ground movements while maintaining specific temperature ranges of 2 to 8 degrees Celsius, 15 to 25 degrees Celsius, and frozen, according to the company.
The investment is the latest chapter in a broader strategic pivot for UPS, which is building a real-time digital twin of its entire logistics network and has spent billions on acquisitions to become what it calls the world’s leading provider of complex healthcare logistics. The company is targeting $20 billion in healthcare revenue by the end of 2026, a figure that would represent roughly 18 per cent of its total sales.
Why cold chain matters now
The pharmaceutical industry is shifting toward medicines that spoil. Roughly one in three newly approved drugs is now a biologic, and more than 85 per cent of those require temperature-controlled handling, according to PharmaSource.
